Daily use of high-potency cannabis is associated with more positive symptoms in first-episode psychosis patients: the EU-GEI case–control study

Diego Quattrone1,2,3, Laura Ferraro4, Giada Tripoli5, Caterina La Cascia4, Harriet Quigley5, Andrea Quattrone6, Hannah E. Jongsma7, Simona Del Peschio8, Giusy Gatto9, EU-GEI group1,4 *, Charlotte Gayer-Anderson9, Peter B. Jones10,11, James B. Kirkbride7, Daniele La Barbera4, Ilaria Tarricone12, Domenico Berardi12, Sarah Tosato13, Antonio Lasalvia13, Andrea Szöke14, Celso Arango15, Miquel Bernardo16, Julio Bobes17, Cristina Marta Del Ben18, Paulo Rossi Menezes18, Pierre-Michel Llorca19, Jose Luis Santos20, Julio Sanjuán21, Andrea Tortelli22, Eva Velthorst23,24, Lieve de Haan23, Bart P. F. Rutten25, Michael T. Lynskey26, Tom P. Freeman26,27, Pak C. Sham28,29, Alastair G. Cardno30, Evangelos Vassos1, Jim van Os25,31, Craig Morgan9, Ulrich Reininghaus3,9,25, Cathryn M. Lewis1, Robin M. Murray2,5 and Marta Di Forti21,2

1Social, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, London, SES 8AF, UK; 2National Institute for Health Research (NIHR) Maudsley Biomedical Research Centre, South London and Maudsley NHS Foundation Trust, King’s College London, London, UK; 3Medical Faculty Mannheim, Central Institute of Mental Health, University of Heidelberg, Mannheim, Germany; 4Department of Experimental Biomedicine and Clinical Neuroscience, University of Palermo, Via G. La Loggia 1, 90129 Palermo, Italy; 5Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, De Crespigny Park, Denmark Hill, London, SES 8AF, UK; 6Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, 98100, Messina, Italy; 7PsyLife Group, Division of University College London, 6th Floor, Maple House, 149 Tottenham Court Road, London, W1T 7NF, UK; 8University of Bologna, 40126 Bologna, Italy; 9Department of Health Service and Population Research, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, De Crespigny Park, Denmark Hill, London, SES 8AF, UK; 10Department of Psychiatry, University of Cambridge, Herchel Smith Building for Brain & Mind Sciences, Forvie Site, Robinson Way, Cambridge, CB2 0SZ, UK; 11CAMEO Early Intervention Service, Cambridgeshire & Peterborough NHS Foundation Trust, Cambridge, CB21 5EF, UK; 12Department of Medical and Surgical Science, Psychiatry Unit, Alma Mater Studiorum Università di Bologna, Viale Pepoli 5, 40126 Bologna, Italy; 13Section of Psychiatry, Department of Neuroscience, Biomedicine and Movement, University of Verona, Piazzale L.A. Scuro 10, 37134 Verona, Italy; 14INSERM, U955, Equipe 15, 51 Avenue de Maréchal de Lattre de Tassigny, 94010 Créteil, France; 15Child and Adolescent Psychiatry Department, Institute of Psychiatry and Mental Health, General Universitario Gregorio Marañón, School of Medicine, Universidad Complutense, iSGM, CIBERSAM, C/Doctor Esquerdo 46, 28007 Madrid, Spain; 16Department of Medicine, Barcelona Clinic Schizophrenia Unit, Neuroscience Institute, Hospital Clinic of Barcelona, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Spain; 17Faculty of Medicine and Health Sciences – Psychiatry, Universidad de Oviedo, ISPA, INEUROPA. CIBERSAM, Oviedo, Spain; 18Department of Preventative Medicine, Facultade de Medicina FMUSP, University of São Paulo, São Paulo, Brazil; 19EA 7280 Npsydo, Université Clermont Auvergne, Clermont-Ferrand, France; 20Department of Psychiatry, Servicio de Psiquiatría Hospital ‘Virgen de la Luz’, Cuenca, Spain; 21Department of Psychiatry, School of Medicine, Universidad de Valencia, Centro de Investigacion Biomedica en Red de Salud Mental, Valencia, Spain; 22Institut National de Santé et de Recherche Médicale, Unité de Psychiatrie, Early Psychosis Section, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands; 23Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, New York, USA; 24Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, South Limburg Mental Health Research and Teaching Network, Maastricht University Medical Centre, P.O. Box 616, 6200 MD Maastricht, The Netherlands; 25National Addiction Centre, Institute of Psychiatry, Psychology & Neuroscience, King’s College London, 4 Windsor Walk, London, SES 8BB, UK; 26Department of Psychology, University of Bath, 10 West, Bath, BA2 7AY, UK; 27Department of Psychiatry, University of Hong Kong, Hong Kong, China; 28Li KaShing Faculty of Medicine, Centre for Genomic Sciences, The University of Hong Kong, Hong Kong, China; 29Academic Unit of Psychiatry and Behavioural Sciences, University of Leeds, Leeds, UK and 30Brain Centre Rudolf Magnus, Utrecht University Medical Centre, Utrecht, The Netherlands

*See at the end of the Article for more details.

Cite this article: Quattrone D et al (2021). Daily use of high-potency cannabis is associated with more positive symptoms in first-episode psychosis patients: the EU-GEI case–control study. Psychological Medicine 51, 1329–1337. https://doi.org/10.1017/S0033291720000082

Accepted: 8 January 2020
First published online: 18 March 2020

Key words: Cannabis use; cannabis-associated psychosis; psychopathology; psychotic experiences; symptom dimensions; first episode psychosis

Author for correspondence:
Diego Quattrone,
E-mail: diego.quattrone@kcl.ac.uk

© The Author(s) 2020. Published by Cambridge University Press. This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract

Background. Daily use of high-potency cannabis has been reported to carry a high risk for developing a psychotic disorder. However, the evidence is mixed on whether any pattern of cannabis use is associated with a particular symptomatology in first-episode psychosis (FEP) patients.

Method. We analysed data from 901 FEP patients and 1235 controls recruited across six countries, as part of the European Network of National Schizophrenia Networks Studying Gene-Environment Interactions (EU-GEI) study. We used item response modelling to estimate two bifactor models, which included general and specific dimensions of psychotic symptoms in patients and psychotic experiences in controls. The associations between these dimensions and cannabis use were evaluated using linear mixed-effects models analyses.

Results. In patients, there was a linear relationship between the positive symptom dimension and the extent of lifetime exposure to cannabis, with daily users of high-potency cannabis having the highest score ($B = 0.35; 95\% \text{CI} 0.14–0.56$). Moreover, negative symptoms were more common among patients who never used cannabis compared with those with any pattern of use ($B = -0.22; 95\% \text{CI} -0.37 \text{ to } -0.07$). In controls, psychotic experiences were associated with current use of cannabis but not with the extent of lifetime use. Neither patients nor controls presented differences in depressive dimension related to cannabis use.

Conclusions. Our findings provide the first large-scale evidence that FEP patients with a history of daily use of high-potency cannabis present with more positive and less negative symptoms, compared with those who never used cannabis or used low-potency types.

Introduction

There is compelling evidence to suggest that cannabis use is associated with psychotic disorders (Marconi, Di Forti, Lewis, Murray, & Vassos, 2016). However, it is unclear whether cannabis use is a ‘modifier’ factor that affects symptom presentation of psychotic disorders. The existence of a pattern of psychotic symptomatology particularly associated with cannabis has been described in several case series (Bernhardson & Gunne, 1972; Chopra & Smith, 1974; Spencer, 1971; Talbott & Teague, 1969; Bromberg, 1934). Nevertheless, case and cohort studies have found mixed results as to whether (Addington & Addington, 2007; Bersani, Orlandi, Kotzalidis, & Pancheri, 2002; Foti, Kotov, Guey, & Bromet, 2010; Grech, Van Os, Jones, Lewis, & Murray, 2005; Green et al., 2004; Negrete, Knapp, Douglas, & Smith, 1986; Peralta & Cuesta, 1992; Ringen et al., 2016; Seddon et al., 2016) or not (Barrowclough, Gregg, Lobban, Bucci, & Emsley, 2015; Boydell et al., 2007; Dubertret, Bidad, Ades, & Gorwood, 2006; Stirling, Lewis, Hopkins, & White, 2005; Thornicroft, Meadows, & Politi, 1992; Tosato et al., 2013; van Dijk, Koeter, Hijman, Kahn, & van den Brink, 2012) psychotic patients using cannabis present with more positive symptoms than those not using cannabis. Moreover, there is mixed evidence of any relationship between cannabis use and negative symptoms in psychosis. Some reports suggest fewer negative symptoms in patients with psychosis who use cannabis (Bersani et al., 2002; Green et al., 2004; Peralta & Cuesta, 1992), which is consistent with having enough social skills to obtain the substance (Murray et al., 2017). However, this association has not been confirmed in other studies (Grech et al., 2005; Seddon et al., 2016) and others even reported a positive association (Ringen et al., 2016).

These inconsistencies might be explained by differences in study design and methods. For example, only a few findings were based on first-episode psychosis (FEP) patients (Addington & Addington, 2007; Grech et al., 2005; Seddon et al., 2016; Tosato et al., 2013), which minimize selection and recall bias, and the confounding effect of antipsychotic drugs on symptoms. In addition, a meta-analysis of longitudinal studies concluded that most examinations lacked sufficient power to detect an effect of cannabis on symptoms, or inadequately controlled for potential confounders (Zammit et al., 2008). Furthermore, although a few studies included information on the frequency of use, all failed to obtain detailed information on the lifetime pattern of cannabis use, especially on the type and strength of cannabis used. Of note, potent cannabis varieties, with high concentrations of Delta-9-Tetrahydrocannabinol (A9-THC), have been associated with the most harm to mental health (Di Forti et al., 2015; Freeman et al., 2018) and, in recent years, these potent types have become more available worldwide (Elsohly et al., 2016; Freeman et al., 2019; Potter, Hammond, Tuffnell, Walker, & Di Forti, 2018). Finally, no studies have used factor analysis of observed symptoms to evaluate to what extent cannabis use is a factor influencing the clinical heterogeneity of psychosis.

On the other hand, in the general population, there are consistent findings regarding the association between cannabis use and psychotic experiences (Ragazzi, Shuhama, Menezes, & Del-Ben, 2018). However, most studies had limited geographical coverage and the examined population was scarcely representative of the population at risk of psychosis (Ragazzi et al., 2018).

In this study, we set out to clarify the association between detailed patterns of cannabis use and transdiagnostic symptom dimensions in a large multinational FEP sample. In addition, we examine the association between detailed patterns of cannabis use and subclinical symptom dimensions in a large sample of controls representative of the population at risk in each catchment area.

Specifically, we sought to test the hypotheses that: (1) positive psychotic symptoms are more common among FEP patients with more frequent lifetime use of cannabis and greater exposure to high-potency varieties; (2) positive psychotic experiences are more common in population controls with a recent use of cannabis, who would be more resilient to the long-term effects of cannabis; (3) negative symptoms are more common among those patients who have never used cannabis.

Methods

Study design and participants

This analysis is based on the incidence and case–control study work package of the EUropean network of national schizophrenia networks studying Gene-Environment Interactions (EU-GEI).

FEP individuals were identified between 2010 and 2015 across six countries to examine the incidence rates of schizophrenia and other psychotic disorders (Jongsma et al., 2018), and symptomatology at psychosis onset (Quattrone et al., 2019). To examine the risk factors, we sought to perform an extensive assessment on approximately 1000 FEP patients and 1000 population-based controls during the same time period.
Patients were included in the case–control study if they met the following criteria during the recruitment period: (a) aged between 18 and 64 years; (b) presentation with a clinical diagnosis for an untreated FEP, even if longstanding [International Statistical Classification of Diseases and Related Health Problems, Tenth Revision (ICD-10) codes F20–F33]; (c) resident within the catchment area. Exclusion criteria were: (a) previous contact with psychiatric services for psychosis; (b) psychotic symptoms originating from an identified organic condition; and (c) transient psychotic symptoms resulting from acute intoxication (ICD-10: F1x.5).

The recruitment of controls followed a mixture of random and quota sampling methods, in order to achieve the best possible representativeness in age, sex and ethnicity of the population living in each catchment area. The identification process varied by site and was based on locally available sampling frames, including mostly the use of lists of all postal addresses and general practitioners’ lists from randomly selected surgeries. When these resources were not fully available, Internet and newspapers advertising were used to fill quotas. Exclusion criteria for controls were: (a) diagnosis of a psychotic disorder; (b) ever having been treated for psychotic symptoms.

We analysed data from 11 catchment areas, including urban and less urban populations [i.e. Southeast London, Cambridgeshire and Peterborough (England); central Amsterdam, Gouda and Voorhout (the Netherlands); Bologna municipality, city of Palermo (Italy); Paris (Val-de-Marne), Puy-de-Dôme (France); Madrid (Vallecas), Barcelona (Spain); and Ribeirão Preto (Brazil)]. Further information on the case–control sample and the recruitment strategies is included in the online Supplementary material.

**Measures**

Data on age, sex and ethnicity were collected using a modified version of the Medical Research Council Sociodemographic Schedule (Mallett, 1997). The OPerational CRITeria (OPCRIT) system (McGuffin, Farmer, & Harvey, 1991) was used by centrally trained investigators, whose reliability was assessed before and throughout the study (k = 0.7), to assess psychopathology in the first 4 weeks after the onset and generate research-based diagnoses based on different diagnostic classification systems. The Community Assessment of Psychic Experiences (CAPE) (Stefanis et al., 2002) was administered to controls to self-report their psychotic experiences. The reliability of the CAPE is good for all the languages spoken in the countries forming part of the EU-GEI study (http://cape42.homestead.com).

A modified version of the Cannabis Experience Questionnaire (CEQEU-GEI) (Di Forti et al., 2009) was used by investigators to collect extensive information on the patterns of use of cannabis and other drugs. We used six measures of cannabis use (online Supplementary Table S2), including a variable measuring specific patterns of cannabis exposure by combining the frequency of use with the potency of cannabis. As illustrated in the Supplementary material, the cannabis potency variable was based on the data published in the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) (Di Forti et al., 2019; European Monitoring Centre for Drugs & Drug Addiction, 2013).

We selected confounders based on their possible association with cannabis use and/or symptom dimensions. These included: sex; age; ethnicity; use of stimulants, hallucinogens, ketamine, cocaine, crack and novel psychoactive substances; current use of tobacco cigarettes (smoking 10 cigarettes or more per day = 1); and current use of alcohol (drinking 10 alcohol units or more per week = 1).

**Statistical analysis**

**Dimensions of psychotic symptoms in patients and psychotic experiences in controls**

Data from OPCRIT and CAPE were analysed using multidimensional item response modelling in Mplus, version 7.4 (Muthén & Muthén, 2012), to estimate two bifactor models, based on the associations among observer ratings of psychotic symptoms in patients and self-ratings of psychotic experiences in controls. This methodology is described in full in our EU-GEI paper on symptom dimensions in FEP patients (Quattrone et al., 2019), and it was likewise applied to psychotic experiences in population controls. Briefly, CAPE items were dichotomized as 0 ‘absent’ or 1 ‘present’. In order to ensure sufficient covariance coverage for item response modelling, we used items with a valid frequency of ‘present’ ≥10% in our sample, and we excluded items with low correlation values (<0.3) based on the examination of the item correlation matrix. As in the previous analysis in patients, the bifactor solution was compared with other solutions (i.e. unidimensional, multidimensional and hierarchical models) using Log-Likelihood (LL), Akaike Information Criterion (AIC), Bayesian Information Criterion (BIC) and Sample-size Adjusted BIC (SABIC) as model fit statistics. Path diagrams that illustrate these models are presented in online Supplementary Fig. S1. Reliability and strength indices such as McDonald’s omega (ω) (Rodriguez, Reise, & Haviland, 2016), omega hierarchical (ω_h) (Rodriguez et al., 2016) and index H (Hancock & Mueller, 2001) were computed to determine: (1) the proportion of common variance accounted by general and specific symptom dimensions; (2) the proportion of reliable variance accounted by the general dimension not unduly affected by the specific dimensions; (3) the proportion of reliable variance accounted for by each specific dimension not unduly affected by the general and all the other specific dimensions; (4) the overall reliability and replicability of the bifactor construct of psychosis-like experiences. Finally, we generated factor scores for one general psychotic experience dimension and three specific dimensions of positive, negative and depressive psychotic experiences.

For patients, we used the previously generated factor scores for one general psychosis dimension and five specific dimensions of positive, negative, disorganized, manic and depressive symptoms (Quattrone et al., 2019).

**Symptom dimensions and cannabis use**

We evaluated the relationship between psychotic symptom dimensions in patients, or psychotic experience dimensions in controls, and cannabis use using linear mixed-effects models in STATA14 (StataCorp, 2015). We specifically modelled symptom dimension scores as a function of each of the six measures of cannabis use. We then evaluated the combined effect of frequency of use and potency of cannabis. To account for the non-independence of symptom profiles of subjects assessed within the same country (e.g. due to cultural similarities), and for the potential within-site correlation (e.g. due to context factors), we fitted a three-level mixed model, where the random effect encompassed two levels of random intercepts: one due to the countries, and another due to the sites within the countries. Finally, we used
the Benjamini–Hochberg (B-H) procedure to reduce the false discovery rate, which we set at 5%.

**Results**

**Sample characteristics**

We analysed data from 901 FEP patients and 1235 controls. The main socio-demographic characteristics and history of substance misuse of patients and controls are presented in online Supplementary Table S1. Online Supplementary Tables S3 and S5 show the sample prevalence of psychotic experiences in controls and of psychotic symptoms in patients.

**Bifactor model of psychotic experiences in controls**

Online Supplementary Table S4 shows that, as in our previous analysis of the OPCRIT items (Quattrone et al., 2019), the bifactor model provided the best fit for the CAPE items, as illustrated by AIC, BIC and SABIC substantially lower compared with competing models. This solution explained 60% of the unique variance. In addition, Fig. 1 shows that, within the bifactor model, the explained variance was due to individual differences mostly on the general psychotic experience dimension. This is illustrated by the relative $\omega$ coefficient, which, for example, showed that 85% of the reliable variance was due to the general dimension when partitioning out the variability in scores due to the specific dimensions. Moreover, factor loadings of moderate to high magnitude were observed for most items on the general psychotic experience dimension, whereas factor loadings of a smaller magnitude were observed for the specific dimensions (Fig. 1).

Consistently, the index $H$, which is a measure of the construct reliability and replicability across studies (Hancock & Mueller, 2001), was very high for the general dimension (0.92), moderate for positive (0.78) and negative (0.71) dimensions and lower for the depressive dimension (0.41).

**Symptom dimensions in patients by a pattern of cannabis use**

Models’ results are presented in Table 1 which shows that:

(1) There were no differences in the distribution of positive symptoms according to early age at first use ($\leq 15$ years old), nor, after B-H correction, according to ever or current
use of cannabis. However, positive symptoms were more common among patients who spent more than 20 euros per week on cannabis ($B = 0.3;\ 95\%\ CI\ 0.11–0.48;\ p = 0.001$).

(2) Fewer negative symptoms were observed among those patients who used cannabis at least once compared with those who never tried ($B = -0.22;\ 95\%\ CI\ -0.37\ to\ -0.07;\ p = 0.004$). Early age at first use and current use of cannabis was not associated with negative symptomatology.

(3) Manic symptoms were more frequent among patients who had ever used cannabis ($B = 0.22;\ 95\%\ CI\ 0.08–0.36;\ p = 0.002$).

(4) There were no differences in the distribution of the scores on the depressive, disorganization and general psychosis dimensions according to any measure of cannabis use.

Psychotic experience dimensions in population controls by patterns of cannabis use

Models’ results are presented in Table 2, which shows that:

(1) There were no differences in the distribution of positive psychotic experiences according to ever use of cannabis or early age at first use (≤ 15 years old). However, positive psychotic experiences were more commonly reported by subjects who currently used cannabis ($B = 0.33;\ 95\%\ CI\ 0.15–0.51;\ p < 0.001$) and who spent more than 20 euros per week on cannabis ($B = 0.39;\ 95\%\ CI\ 0.09–0.69;\ p = 0.011$).

(2) There were no differences in the distribution of the depressive and negative experiences in population controls according to cannabis use.

Symptom dimensions by frequency of use and potency of cannabis

The independent effects of frequency of use and potency of cannabis are reported in online Supplementary Tables S6.1 and S6.2, and online Supplementary Fig. S2, showing that, only in patients, positive symptoms were more common in those who used cannabis on a daily basis and exposed to high-potency varieties.

Testing the combined ‘type-frequency’ variable in patients, we found evidence of a linear relationship between the positive symptom dimension and the extent of exposure to cannabis, with daily users of high-potency cannabis showing the highest score ($B = 0.35;\ 95\%\ CI\ 0.14–0.56;\ p = 0.001$). Therefore, we introduced a contrast operator and plotted the exposure–response relationship for positive symptoms (Fig. 2), by comparing the predictive margins of the adjusted mean of each group against the grand adjusted mean of all groups. Figure 2 shows that the adjusted mean for daily users of high-potency cannabis was 0.2 units greater than the grand adjusted mean. Moreover, the adjusted means for the groups who never or rarely used cannabis were respectively 0.16 or 0.18 units lower than the grand adjusted mean.

A negative relationship between the negative symptom dimension score and patterns of cannabis use was also observed in patients. Figure 3 shows that patients with psychosis who never used cannabis had more negative symptoms either compared with the grand adjusted mean or with any pattern of cannabis use.

Discussion

Principal findings

This is the first multinational study analysing data on the potency of cannabis and its dose-effect relationship with dimensions of symptoms in FEP patients, and dimensions of psychotic experiences in population controls. We provide the first evidence that: (1) in patients, a positive correlation exists between the extent of premorbid cannabis use and the score on the positive symptom dimension, with daily users of high-potency cannabis showing the most positive symptoms at FEP; (2) psychotic experiences in non-clinical populations are associated with the current use of cannabis but are independent of the extent of lifetime exposure to cannabis; (3) negative symptoms at FEP are more common in patients who have never tried cannabis; (4) depressive symptoms are independent of any pattern of use of cannabis.

Limitations

Our findings must be considered in the context of two main limitations. First, individual data on patterns of cannabis use are not validated with biological samples. However, biological tests are not considered the gold standard method for such a validation (Large et al., 2012) and do not allow one to ascertain the extent of cannabis use over the years (Taylor, Sullivan, Ring, Macleod, & Hickman, 2017). Moreover, studies combining self-report and laboratory data support the reliability of subjects in reporting the type of cannabis they use (Freeman et al., 2014; Wofford et al., 1999). Second, we did not take into account the cannabidiol (CBD) contribution to the potency variable, as official data on its

---

Table 1. Symptom dimensions in FEP patients by measures of cannabis use

<table>
<thead>
<tr>
<th>Symptom dimension</th>
<th>Ever used cannabis ($B$ (95% CI))</th>
<th>Current use of cannabis ($B$ (95% CI))</th>
<th>Age at first use of cannabis ($B$ (95% CI))</th>
<th>Money used for cannabis ($B$ (95% CI))</th>
</tr>
</thead>
<tbody>
<tr>
<td>Positive</td>
<td>0.16* (0 to 0.31)</td>
<td>0.21* (0.04–0.37)</td>
<td>0.05 (–0.13 to 0.22)</td>
<td>0.3** (0.11–0.48)</td>
</tr>
<tr>
<td>Negative</td>
<td>$-0.22**$ (–0.37 to –0.07)</td>
<td>–0.09 (–0.26 to 0.07)</td>
<td>0.07 (–0.09 to 0.22)</td>
<td>0.07 (–0.12 to 0.25)</td>
</tr>
<tr>
<td>Depressive</td>
<td>–0.08 (–0.24 to 0.08)</td>
<td>–0.08 (–0.22 to 0.06)</td>
<td>–0.09 (–0.23 to 0.05)</td>
<td>–0.11 (–0.29 to 0.06)</td>
</tr>
<tr>
<td>Disorganization</td>
<td>–0.01 (–0.24 to 0.03)</td>
<td>0.01 (–0.05 to 0.26)</td>
<td>0.11 (–0.06 to 0.28)</td>
<td>0.1 (–0.17 to 0.19)</td>
</tr>
<tr>
<td>Manic</td>
<td>0.22** (0.08–0.36)</td>
<td>0.12 (–0.02 to 0.27)</td>
<td>–0.09 (–0.25 to 0.07)</td>
<td>0.05 (–0.11 to 0.22)</td>
</tr>
<tr>
<td>General factor</td>
<td>0.05 (–0.06 to 0.17)</td>
<td>0.02 (–0.1 to 0.14)</td>
<td>–0.06 (–0.09 to 0.22)</td>
<td>0.03 (–0.11 to 0.17)</td>
</tr>
</tbody>
</table>

*All models were adjusted for age, sex, ethnicity, use of other recreational/illicit substances and diagnosis. Models were random-intercept models that included two random effects to allow symptomatology to vary across countries and across sites within countries but assumed that individual-level exposure to cannabis had a fixed effect across the entire sample. Significance: *$p < 0.05$, **$p < 0.01$, ***$p < 0.001$; $P$-values nominally significant after Benjamini-Hochberg procedure are showed in bold.
content in the different cannabis varieties were not available in most study sites; CBD might counterbalance Δ9-THC effects and minimize both psychotic experiences (Schubart et al., 2011) and symptoms (McGuire et al., 2018).

**Comparison with previous research**

We extend previous research on cannabis and psychotic symptoms to a multinational sample confirming the association between cannabis use and positive symptoms of FEP (Ringen et al., 2016; Seddon et al., 2016). Our results are in line with Schoeler et al. (2016), who carefully scrutinized the literature on the effect of continuation of cannabis use after FEP, concluding that this would be associated with a more severe positive symptomatology (Schoeler et al., 2016). That said, any comparison with previous research is limited by the lack of information on frequency and potency in all the previous studies along with subjects’ exposure to more potent varieties of cannabis in recent years (Potter et al., 2018). In this respect, we firstly provide some evidence that cannabis affects positive symptoms in a dose–response manner, further supporting the converging epidemiological and experimental evidence that the use of cannabis with high content of Δ9-THC has a more detrimental effect than other varieties (Di Forti et al., 2009; Freeman et al., 2018; Morrison et al., 2009).

We also report evidence in a multinational FEP sample of an association between lifetime cannabis use and fewer negative symptoms, the latter often considered as a marker of greater neurodevelopmental impairment in psychosis. Two opposite interpretations may be considered.

First, some authors have suggested that people suffering a psychotic disorder might abuse cannabis as an attempt to self-medicate negative symptoms, and thus the observed reduction in negative symptomatology would be an epiphenomenon due to the cannabis intake itself (Peralta & Cuesta, 1992).

Alternatively, psychotic disorders may be characterized by less neurodevelopmental features when associated with cannabis use (Ferraro et al., 2013; Ferraro et al., 2019; Murray et al., 2017; Ruiz-Veguilla, Callado, & Ferrin, 2012), hence FEP patients who do not initiate to use cannabis would present more negative symptoms.

The lack of a dose dependency in our study appears to speak against the first and in favour of the second possibility, as the difference holds between those who never obtained cannabis and those who used it only once. Moreover, negative symptoms would reduce the social and instrumental skills that were

---

**Table 2. Psychotic experience dimensions in controls by cannabis use**

<table>
<thead>
<tr>
<th>Psychotic experience dimension</th>
<th>Ever used cannabis (B) (95% CI)</th>
<th>Current use of cannabis (B) (95% CI)</th>
<th>Age at first use of cannabis (B) (95% CI)</th>
<th>Money used for cannabis (B) (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Positive</td>
<td>0.05 (−0.06 to 0.17)</td>
<td>0.33*** (0.15–0.51)</td>
<td>0.08 (−0.11 to 0.25)</td>
<td>0.39* (0.09–0.69)</td>
</tr>
<tr>
<td>Negative</td>
<td>0.11 (−0.01 to 0.24)</td>
<td>0.16 (−0.03 to 0.36)</td>
<td>−0.11 (−0.29 to 0.07)</td>
<td>−0.12 (−0.2 to 0.44)</td>
</tr>
<tr>
<td>Depressive</td>
<td>0.09 (−0.03 to 0.21)</td>
<td>0.01 (−0.19 to 0.20)</td>
<td>−0.02 (−0.21 to 0.16)</td>
<td>−0.02 (−0.3 to 0.35)</td>
</tr>
<tr>
<td>General factor</td>
<td>0.04 (−0.08 to 0.17)</td>
<td>0.13 (−0.07 to 0.33)</td>
<td>0.08 (−0.11 to 0.22)</td>
<td>0.15 (−0.18 to 0.48)</td>
</tr>
</tbody>
</table>

*All models were adjusted for age, sex, ethnicity and use of other recreational/illicit substances. Models were random-intercept models that included two random effects to allow symptomatology to vary across countries and across sites within countries but assumed that individual-level exposure to cannabis had a fixed effect across the entire sample. Significance: *\(p<0.05\), **\(p<0.01\), ***\(p<0.001\); \(P\)-values nominally significant after Benjamini-Hochberg procedure are showed in bold.

---

**Fig. 2.** Positive symptom dimension in cases by patterns of cannabis use. Explanatory note: the positive symptom dimension predicted mean of each group of patterns of cannabis use is plotted against the predicted grand mean of all groups (represented by the red line). The positive value for the contrast of daily use of high-potency cannabis indicates more positive symptomatology in this group. On the other hand, negative values for the contrasts of the first two groups indicates less positive symptomatology when there is less exposure to cannabis. These differences are relevant, as indicated by 95% confidence intervals that do not overlap with zero. The model was a random intercept model which allowed symptomatology to vary across countries and sites within countries, but it assumed that frequency of use and type of cannabis had an individual fixed effect. Values were adjusted for age, sex, ethnicity, diagnosis and use of other recreational/illicit substances.
necessary to illegally obtain cannabis and sustain its use in all the countries included in the study, except Holland.

Last, we report that the cumulative exposure to cannabis does not impact on psychotic experiences in controls. One could of course argue that the largest proportion of subjects with the harmful pattern of cannabis use were patients. However, further research is needed to look into plausible mechanisms of resilience to the psychotogenic effect of cannabis as observed in our controls, who report psychotic experiences if current users but do not seem to accumulate a risk over life time cannabis use and develop psychotic disorders. Indeed, future studies should aim to: (1) investigate if and how genetic factors, plausibly regulating the endocannabinoid and dopamine systems, pose a small subset of cannabis users at high risk of developing a psychotic disorders with particular symptomatology; (2) clarify over the course of the disorder whether differences in symptomatology between current and former cannabis users may be related to residual cannabis effects.

Implications

The novelty of our study is based on our examination of data on lifetime frequency of cannabis use and on the type of the cannabis used; the availability of high-potency types is increasing worldwide. For instance, a recent potency study revealed that in London, the high-potency type of cannabis called skunk has now taken up 96% of the street market (Potter et al., 2018). The EMCDDA has described a European cannabis market characterized by potent varieties (European Monitoring Centre for Drugs and Drug Addiction, 2013) like those present in Amsterdam coffee shops that can reach up to 39% of THC. Indeed, as daily use of high-potency cannabis has been associated with high rates of psychotic disorders across Europe (Di Forti et al., 2019), here we show that in FEP patients daily use of high-potency cannabis drives a high score on the positive symptom dimension. Further research should aim to determine biological mechanisms underlying how cannabis contribute to a particular clinical presentation of psychosis. Meanwhile, translating current findings into clinical practice, symptom dimension scores can be used to stratify patients and develop secondary prevention schemes for cannabis-associated psychosis.

Supplementary material. The supplementary material for this article can be found at https://doi.org/10.1017/S0033291720000082.

Financial support. The work was supported by: Clinician Scientist Medical Research Council fellowship (project reference MR/M008436/1) to MDF; the National Institute for Health Research (NIHR) Collaboration for Leadership in Applied Health Research and Care South London at King’s College Hospital NHS Foundation Trust to DQ; DFG Heisenberg professorship (no. 389624707) to UR. National Institute for Health Research (NIHR) Biomedical Research Centre for Mental Health at South London and Maudsley NHS Foundation Trust and King’s College London. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care. The EU-GEI Project is funded by the European Community’s Seventh Framework Programme under grant agreement No. HEALTH-F2-2010-241909 (Project EU-GEI). The Brazilian study was funded by the São Paulo Research Foundation under grant number 2012/0417-0. Funders were not involved in the design and conduct of the study; collection, management, analysis and interpretation of the data; preparation, review or approval of the manuscript and decision to submit the manuscript for publication.

Conflict of interest. None.

References


**EU-GEI group authorship includes**

Kathryn Hubbard¹, Stephanie Beards¹, Simona A. Stilo², Mara Parellada³, David Fraguas³, Marta Rapado Castro⁴, Álvaro Andreu-Bernabeu⁵, Gonzalo López⁶, Mario Mattei⁵, Emiliano González⁶, Manuel Durán-Cutilla⁵, Covadonga M. Díaz-Caneja⁷, Pedro Cuadrado⁷, José Juan Rodríguez Solano⁷, Angel Carracedo⁷, Javier Costas⁷, Emilio Sánchez⁷, Silvia Amoretti⁸, David Fraguas³, Marta Rapado Castro³, Álvaro Andreu-Bernabeu³, Gonzalo Solano⁵, Angel Carracedo³, Javier Costas⁷, Emilio Sánchez⁷, Silvia Amoretti⁸, Andrés Fraguas³, Marta Rapado Castro³, Álvaro Andreu-Bernabeu³, Gonzalo Solano⁵, Álvaro Andreu-Bernabeu³, Gonzalo Solano⁵, Angel Carracedo³, Javier Costas⁷, Emilio Sánchez⁷, Silvia Amoretti⁸, Andrés Fraguas³, Marta Rapado Castro³, Álvaro Andreu-Bernabeu³, Gonzalo Solano⁵, Angel Carracedo³, Javier Costas⁷, Emilio Sánchez⁷, Silvia Amoretti⁸, Fabio Seminerio²², Camila Marcelino Loureiro²⁴, Rosana Shuhama²⁴, Mirella Ruggeri²⁴, Chiara Bonetto²⁴, Dorian Cristofalo²⁴, Marco Seri²⁴, Giuseppe D’Andrea²⁴, Michael C O’Donovan²⁸, Alexander I Richards²⁸

¹Department of Health Service and Population Research, Institute of Psychiatry, King’s College London, De Crespigny Park, Denmark Hill, London, United Kingdom, SE5 8AF

²Department of Psychosis Studies, Institute of Psychiatry, King’s College London, De Crespigny Park, Denmark Hill, London, United Kingdom, SE5 8AF

³Department of Child and Adolescent Psychiatry, Hospital General Universitario Gregorio Marañón, School of Medicine, Universidad Complutense, ISG (CIBERSAM), C/Doctor Esquerdo 46, 28007 Madrid, Spain

⁴Villa de Vallecas Mental Health Department, Villa de Vallecas Mental Health Centre, Hospital Universitario Infanta Leonor / Hospital Virgen de la Torre, C/San Claudio 154, 28038 Madrid, Spain

⁵Puente de Vallecas Mental Health Department, Hospital Universitario Infanta Leonor / Hospital Virgen de la Torre, Centro de Salud Mental Puente de Vallecas, C/Peña Gorbue 4, 28018 Madrid, Spain

⁶Fundación Pública Galega de Medicina Xenómica, Hospital Clínico Universitario, Choupana s/n, 15782 Santiago de Compostela, Spain

⁷Department of Psychiatry, Hospital General Universitario Gregorio Marañón, School of Medicine, Universidad Complutense, ISG (CIBERSAM), C/Doctor Esquerdo 46, 28007 Madrid, Spain

⁸Department of Psychiatry, Hospital Clinic, IDIBAPS, Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Universidade de Barcelona, C/Vallcarrol 170, escalera 9, planta 6, 08036 Barcelona, Spain

⁹Department of Psychiatry, School of Medicine, Universidade de Valencia, Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), C/ Avda. Blasco Ibáñez 15, 46010 Valencia, Spain

¹⁰Department of Medicine, Psychiatry Area, School of Medicine, Universidad de Oviedo, Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), C/Julián Clavería s/n, 33006 Oviedo, Spain

¹¹Department of Psychiatry, Service of Psiquiatría Hospital ‘Virgen de la Luz’, C/Hermandad de Donantes de Sangre, 16002 Cuenca, Spain

¹²Department of Psychiatry, Early Psychosis Section, Academic Medical Centre, University of Amsterdam, Meibergdreef 5, 1105 AZ Amsterdam, The Netherlands

¹³Rivierduinen Centre for Mental Health, Leiden, Sandifordtred 19, 2333 ZZ Leiden, The Netherlands

¹⁴Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, South Limburg Mental Health Research and Teaching Network, Maastricht University Medical Centre, P.O. Box 616, 6200 MD Maastricht, The Netherlands

¹⁵AP-HP, Groupe Hospitalier ‘Mondor’, Pôle de Psychiatrie, 51 Avenue de Maréchal de Lattre de Tassigny, 94010 Créteil, France

¹⁶INSERM, U955, Equipe 15, 51 Avenue de Maréchal de Lattre de Tassigny, 94010 Créteil, France

¹⁷Faculté de Médecine, Université Paris-Est, 51 Avenue de Maréchal de Lattre de Tassigny, 94010 Créteil, France

¹⁸Fondation Fonamental, 40 Rue de Mesly, 94000 Créteil, France

¹⁹CMF B CHU, BP 69, 63003 Clermont Ferrand, Cedex 1, France

²⁰Établissement Public de Santé Maison Blanche, Paris, France

²¹Université Clermont Auvergne, EA 7280, Clermont-Ferrand, 63000, France

²²Department of Experimental Biomedicine and Clinical Neurosciences, Section of Psychiatry, University of Palermo, Via G. La Loggia n.1, 90129 Palermo, Italy

²³Unit of Psychiatry, ‘P. Giaccone’ General Hospital, Via G. La Loggia n.1, 90129 Palermo, Italy

²⁴Department of Neuromecanics and Biomechanics, Faculty of Medicine of Ribeirão Preto, Universidade de São Paulo, Av. Bandeirantes, 3900 -Monte Alegre- CEP 14049-900, Ribeirão Preto, SP, Brasil

²⁵Núcleo de Pesquisa em Saúde Mental Populacional, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Av. Bandeirantes, 3900 -Monte Alegre- CEP 14049-900, Ribeirão Preto, SP, Brasil

²⁶Section of Psychiatry, Department of Neurosciences, Biomedicine and Movement, University of Verona, Piazzale L.A. Scuro 10, 37134 Verona, Italy

²⁷Division of Psychological Medicine and Clinical Neurosciences, MRC Centre for Neuropsychiatric Genetics and Genomics, Cardiff University, Cardiff CF24 4HQ, UK

https://doi.org/10.1017/S0033291720000082 Published online by Cambridge University Press